Sweden · Delayed Price · Currency is SEK Immunovia AB Earnings Call Transcripts
Fiscal Year 2026
-
Q1 2026 saw 169% revenue growth and improved operating loss, driven by increased PancreaSure adoption and disciplined cost control. Strategic focus remains on expanding U.S. market penetration, securing reimbursement, and forming commercialization partnerships, with a strong cash position supporting operations through Q3 2026.
Fiscal Year 2025
-
PancreaSure launched in Q4 2025 with early adoption at 12 centers and strong clinical validation. Revenue remains modest, but a SEK 69.8 million rights issue extends cash runway through Q3 2026. Medicare coverage submission is planned for mid-2026, with significant revenue expected in 2027.
-
PancreaSure's commercial launch marked a major milestone, with rapid adoption by leading cancer centers and strong clinical validation. Financial discipline reduced cash burn, and a successful rights issue secured funding into 2026. Medicare reimbursement progress and further clinical studies are key next steps.
-
PancreaSure's launch marks a pivotal step, with strong scientific validation and initial adoption by top U.S. centers. Q2 saw reduced expenses and a successful rights issue to fund commercialization and reimbursement studies, with revenue expected to shift from patient pay to insurance by 2027.
-
Transitioning to commercialization, the PancreaSure test is set for a September 2025 launch, showing strong clinical performance and doubling its addressable market. Cash reserves are expected to last through Q3, with ongoing efforts to secure partnerships and reimbursement.
-
A clinical validation study in high-risk individuals showed a next-generation blood test detects early-stage pancreatic cancer with 77% sensitivity and 88% specificity, outperforming standard imaging and CA 19-9. Combined with prior data, results support reimbursement, regulatory approval, and a targeted US launch in Q3 2025.
Fiscal Year 2024
-
Clinical validation of a next-generation pancreatic cancer test showed high sensitivity and specificity, outperforming current standards and enabling broader patient applicability. Financials remain stable with successful fundraising, supporting a targeted commercial launch in Q3 2025.
-
A large clinical validation study showed a next-generation blood test for early pancreatic cancer detection achieved 78% sensitivity and 94% specificity in high-risk individuals, outperforming current biomarkers and imaging standards. Performance was even higher in recent samples, and the test is set for U.S. launch next year.
-
Q3 saw major progress in next-gen test validation, with strong sensitivity and specificity results. Financial discipline led to reduced OpEx and cash burn, while a successful rights issue bolstered liquidity. U.S. launch and strategic partnerships are planned for 2025, with clinical validation data due in December.
-
Delivered a next-generation pancreatic cancer test with 98% specificity and 85% sensitivity, reduced OpEx and cash burn, and secured inclusion in a major NIH-funded study. Rights issue underway to fund validation and commercialization, with cash runway through 2024.